The cytokine release syndrome treatment market size has grown rapidly in recent years. It will grow from $1.42 billion in 2025 to $1.61 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to growth in advanced immunotherapy treatments, expansion of car-t cell therapy adoption, availability of corticosteroids for immune modulation, increased clinical awareness of cytokine storms, improvements in critical care infrastructure.
The cytokine release syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $2.66 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing use of next-generation immunotherapies, rising investments in cytokine modulation research, expansion of oncology treatment centers, growing focus on personalized immune management, development of novel anti-inflammatory biologics. Major trends in the forecast period include increasing use of il-6 and il-1 targeted therapies, rising adoption of monoclonal antibodies for crs management, expansion of hospital-based crs treatment protocols, growing integration of early diagnostic monitoring, improved supportive care management strategies.
The increasing prevalence of cancer treatments is expected to drive the growth of the cytokine release syndrome (CRS) treatment market. This is due to the rising global incidence of cancer and advancements in diagnostic technologies, which enable earlier detection and offer a broader range of treatment options. Improved survival rates and expanded healthcare access further contribute to the demand for these therapies. CRS treatment involves supportive care, anti-cytokine therapies, and continuous monitoring to manage symptoms and mitigate the inflammatory response caused by cancer treatments. For instance, in May 2024, the National Health Service (NHS) in the UK reported that almost 340,000 people received their first cancer treatment between April 2023 and March 2024. Additionally, the number of urgent suspected cancer referrals hit a new record high in March 2024, with over 12,500 patients seen per working day. Therefore, the increasing prevalence of cancer treatments is driving growth in the CRS treatment market.
Major companies in the CRS treatment market are advancing drug delivery technologies, such as intravenous infusion, to improve treatment precision, reduce side effects, and enhance patient outcomes. Intravenous infusion enables fast and accurate drug administration into the bloodstream, ensuring prompt therapeutic action. For example, in September 2023, Chugai Pharmaceutical Co. Ltd. received approval from the Ministry of Health, Labor, and Welfare in Japan for Actemra (tocilizumab), an anti-IL-6 receptor monoclonal antibody, to treat CRS induced by various cancer therapies. Actemra Intravenous Infusion is now an approved treatment for CRS resulting from cancer therapies beyond tumor-specific T-cell infusion therapy.
In March 2024, Merck & Co. Inc. acquired Harpoon Therapeutics for $680 million to expand its portfolio of cancer therapies, particularly focusing on T-cell engagers. Harpoon's lead candidate, MK-6070 (formerly HPN328), targets delta-like ligand 3 (DLL3), a protein linked to small cell lung cancer and neuroendocrine tumors. Harpoon Therapeutics specializes in TriTAC-XR, designed for CRS treatment.
Major companies operating in the cytokine release syndrome treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB (publ), Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, bluebird bio Inc.
North America was the largest region in the cytokine release syndrome treatment market in 2025. The regions covered in the cytokine release syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cytokine release syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the cytokine release syndrome treatment market by increasing costs of imported biologics, monoclonal antibodies, active pharmaceutical ingredients, and sterile drug delivery systems. Oncology centers in North America and Europe are most affected due to reliance on imported biologic therapies, while Asia-Pacific faces higher treatment costs linked to limited domestic production. These tariffs are increasing therapy costs and impacting reimbursement dynamics. However, they are also encouraging local biologics manufacturing, regional clinical supply chains, and investment in domestic immunotherapy production capabilities.
The cytokine release syndrome treatment market research report is one of a series of new reports that provides cytokine release syndrome treatment market statistics, including cytokine release syndrome treatment industry global market size, regional shares, competitors with a cytokine release syndrome treatment market share, detailed cytokine release syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cytokine release syndrome treatment industry. This cytokine release syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cytokine release syndrome (CRS) treatment refers to medical interventions aimed at managing and mitigating the severe inflammatory response triggered by cytokine release, which can occur during certain therapies such as CAR-T cell treatments. These treatments help control symptoms, reduce inflammation, and improve patient outcomes during intense cytokine reactions.
The main types of drugs used in cytokine release syndrome treatments include corticosteroids, monoclonal antibodies, and other immunosuppressants. Corticosteroids are drugs that help reduce inflammation by mimicking the effects of hormones produced by the adrenal glands, which regulate inflammation and the immune system. The administration types of corticosteroids include intravenous, subcutaneous, and oral, and they are applied in oncological treatments, autoimmune disorders, and other conditions. The end users of these treatments include hospitals, specialty clinics, and home care settings.
The cytokine release syndrome treatment market consists of revenues earned by entities by providing services such as diagnostic services, clinical trials, hospital and medical services for treatment administration, and regulatory and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cytokine release syndrome treatment also includes sales of supportive medications such as analgesics and antipyretics, anti-cytokine therapies, and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cytokine release syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $2.66 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing use of next-generation immunotherapies, rising investments in cytokine modulation research, expansion of oncology treatment centers, growing focus on personalized immune management, development of novel anti-inflammatory biologics. Major trends in the forecast period include increasing use of il-6 and il-1 targeted therapies, rising adoption of monoclonal antibodies for crs management, expansion of hospital-based crs treatment protocols, growing integration of early diagnostic monitoring, improved supportive care management strategies.
The increasing prevalence of cancer treatments is expected to drive the growth of the cytokine release syndrome (CRS) treatment market. This is due to the rising global incidence of cancer and advancements in diagnostic technologies, which enable earlier detection and offer a broader range of treatment options. Improved survival rates and expanded healthcare access further contribute to the demand for these therapies. CRS treatment involves supportive care, anti-cytokine therapies, and continuous monitoring to manage symptoms and mitigate the inflammatory response caused by cancer treatments. For instance, in May 2024, the National Health Service (NHS) in the UK reported that almost 340,000 people received their first cancer treatment between April 2023 and March 2024. Additionally, the number of urgent suspected cancer referrals hit a new record high in March 2024, with over 12,500 patients seen per working day. Therefore, the increasing prevalence of cancer treatments is driving growth in the CRS treatment market.
Major companies in the CRS treatment market are advancing drug delivery technologies, such as intravenous infusion, to improve treatment precision, reduce side effects, and enhance patient outcomes. Intravenous infusion enables fast and accurate drug administration into the bloodstream, ensuring prompt therapeutic action. For example, in September 2023, Chugai Pharmaceutical Co. Ltd. received approval from the Ministry of Health, Labor, and Welfare in Japan for Actemra (tocilizumab), an anti-IL-6 receptor monoclonal antibody, to treat CRS induced by various cancer therapies. Actemra Intravenous Infusion is now an approved treatment for CRS resulting from cancer therapies beyond tumor-specific T-cell infusion therapy.
In March 2024, Merck & Co. Inc. acquired Harpoon Therapeutics for $680 million to expand its portfolio of cancer therapies, particularly focusing on T-cell engagers. Harpoon's lead candidate, MK-6070 (formerly HPN328), targets delta-like ligand 3 (DLL3), a protein linked to small cell lung cancer and neuroendocrine tumors. Harpoon Therapeutics specializes in TriTAC-XR, designed for CRS treatment.
Major companies operating in the cytokine release syndrome treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB (publ), Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, bluebird bio Inc.
North America was the largest region in the cytokine release syndrome treatment market in 2025. The regions covered in the cytokine release syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cytokine release syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the cytokine release syndrome treatment market by increasing costs of imported biologics, monoclonal antibodies, active pharmaceutical ingredients, and sterile drug delivery systems. Oncology centers in North America and Europe are most affected due to reliance on imported biologic therapies, while Asia-Pacific faces higher treatment costs linked to limited domestic production. These tariffs are increasing therapy costs and impacting reimbursement dynamics. However, they are also encouraging local biologics manufacturing, regional clinical supply chains, and investment in domestic immunotherapy production capabilities.
The cytokine release syndrome treatment market research report is one of a series of new reports that provides cytokine release syndrome treatment market statistics, including cytokine release syndrome treatment industry global market size, regional shares, competitors with a cytokine release syndrome treatment market share, detailed cytokine release syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cytokine release syndrome treatment industry. This cytokine release syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cytokine release syndrome (CRS) treatment refers to medical interventions aimed at managing and mitigating the severe inflammatory response triggered by cytokine release, which can occur during certain therapies such as CAR-T cell treatments. These treatments help control symptoms, reduce inflammation, and improve patient outcomes during intense cytokine reactions.
The main types of drugs used in cytokine release syndrome treatments include corticosteroids, monoclonal antibodies, and other immunosuppressants. Corticosteroids are drugs that help reduce inflammation by mimicking the effects of hormones produced by the adrenal glands, which regulate inflammation and the immune system. The administration types of corticosteroids include intravenous, subcutaneous, and oral, and they are applied in oncological treatments, autoimmune disorders, and other conditions. The end users of these treatments include hospitals, specialty clinics, and home care settings.
The cytokine release syndrome treatment market consists of revenues earned by entities by providing services such as diagnostic services, clinical trials, hospital and medical services for treatment administration, and regulatory and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cytokine release syndrome treatment also includes sales of supportive medications such as analgesics and antipyretics, anti-cytokine therapies, and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cytokine Release Syndrome Treatment Market Characteristics
3. Cytokine Release Syndrome Treatment Market Supply Chain Analysis
4. Global Cytokine Release Syndrome Treatment Market Trends and Strategies
5. Cytokine Release Syndrome Treatment Market Analysis of End Use Industries
7. Global Cytokine Release Syndrome Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cytokine Release Syndrome Treatment Total Addressable Market (TAM) Analysis for the Market
9. Cytokine Release Syndrome Treatment Market Segmentation
10. Cytokine Release Syndrome Treatment Market Regional and Country Analysis
11. Asia-Pacific Cytokine Release Syndrome Treatment Market
12. China Cytokine Release Syndrome Treatment Market
13. India Cytokine Release Syndrome Treatment Market
14. Japan Cytokine Release Syndrome Treatment Market
15. Australia Cytokine Release Syndrome Treatment Market
16. Indonesia Cytokine Release Syndrome Treatment Market
17. South Korea Cytokine Release Syndrome Treatment Market
18. Taiwan Cytokine Release Syndrome Treatment Market
19. South East Asia Cytokine Release Syndrome Treatment Market
20. Western Europe Cytokine Release Syndrome Treatment Market
21. UK Cytokine Release Syndrome Treatment Market
22. Germany Cytokine Release Syndrome Treatment Market
23. France Cytokine Release Syndrome Treatment Market
24. Italy Cytokine Release Syndrome Treatment Market
25. Spain Cytokine Release Syndrome Treatment Market
26. Eastern Europe Cytokine Release Syndrome Treatment Market
27. Russia Cytokine Release Syndrome Treatment Market
28. North America Cytokine Release Syndrome Treatment Market
29. USA Cytokine Release Syndrome Treatment Market
30. Canada Cytokine Release Syndrome Treatment Market
31. South America Cytokine Release Syndrome Treatment Market
32. Brazil Cytokine Release Syndrome Treatment Market
33. Middle East Cytokine Release Syndrome Treatment Market
34. Africa Cytokine Release Syndrome Treatment Market
36. Cytokine Release Syndrome Treatment Market Competitive Landscape and Company Profiles
37. Cytokine Release Syndrome Treatment Market Other Major and Innovative Companies
40. Cytokine Release Syndrome Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Cytokine Release Syndrome Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cytokine release syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cytokine release syndrome treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cytokine release syndrome treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Type: Corticosteroids; Monoclonal Antibodies; Other Immunosuppressants2) By Administration: Intravenous; Subcutaneous; Oral
3) By Application: Oncological Treatments; Autoimmune Disorders; Other Applications
4) By End User: Hospitals; Specialty Clinics; Home Care Settings
Subsegments:
1) Corticosteroids: Prednisone; Dexamethasone; Methylprednisolone2) Monoclonal Antibodies: Tocilizumab (IL-6 Inhibitor); Siltuximab (IL-6 Inhibitor); Anakinra (IL-1 Receptor Antagonist)
3) Other Immunosuppressants: Janus Kinase (JAK) Inhibitors; Calcineurin Inhibitors; Tumor Necrosis Factor (TNF) Inhibitors
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Thermo Fisher Scientific Inc.; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Gilead Sciences Inc.; Amgen Inc.; Regeneron Pharmaceuticals Inc.; Chugai Pharmaceutical Co. Ltd.; Incyte Corporation; Swedish Orphan Biovitrum AB (publ); Bio-Techne Corporation; GenScript Biotech Corporation; Abcam plc; Applied Biological Materials Inc.; Poolbeg Pharma; arigo Biolaboratories Corp.; CytoAgents Inc; bluebird bio Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cytokine Release Syndrome Treatment market report include:- Pfizer Inc.
- Johnson & Johnson
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Sanofi S.A.
- Thermo Fisher Scientific Inc.
- Novartis AG
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Gilead Sciences Inc.
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- Chugai Pharmaceutical Co. Ltd.
- Incyte Corporation
- Swedish Orphan Biovitrum AB (publ)
- Bio-Techne Corporation
- GenScript Biotech Corporation
- Abcam plc
- Applied Biological Materials Inc.
- Poolbeg Pharma
- arigo Biolaboratories Corp.
- CytoAgents Inc
- bluebird bio Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.61 Billion |
| Forecasted Market Value ( USD | $ 2.66 Billion |
| Compound Annual Growth Rate | 13.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
